Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine and Cisplatin in Intrahepatic Cholangiocarcinoma
NCT02256982Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of gemcitabine and cisplatin in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Number of Participants Post Operative/Radiation Therapy Complications at 90 Days. Started Oct 2014; status: terminated.
02
Drugs
gemcitabinecisplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT02256982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256982.